Home Neuronal Signaling Dopamine Receptor agonist Pramipexole dihydrochloride

research use only

Pramipexole dihydrochloride Dopamine Receptor agonist

Cat.No.S5066

Pramipexole dihydrochloride (SND919) is a dopamine agonist of the non-ergoline class indicated for treating Parkinson's disease (PD) and restless legs syndrome (RLS) with Ki values of 3.9 nM, 2.2 nM, 0.5 nM and 5.1 nM for D2S receptor, D2L receptor, D3 receptor and D4 receptor.
Pramipexole dihydrochloride Dopamine Receptor agonist Chemical Structure

Chemical Structure

Molecular Weight: 284.25

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S506601 DMSO]56 mg/mL]false]]]false]]]false Purity: 98%
98

Chemical Information, Storage & Stability

Molecular Weight 284.25 Formula

C10H17N3S.2HCl

 Storage (From the date of receipt)
CAS No. 104632-25-9 -- Storage of Stock Solutions

Synonyms SND919 Smiles CCCNC1CCC2=C(C1)SC(=N2)N.Cl.Cl

Solubility

In vitro
Batch:

DMSO : 56 mg/mL (197.0 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
D3 receptor [1]
(Cell-free)
0.5 nM(Ki)
D2L Receptor [1]
(Cell-free)
2.2 nM(Ki)
D2S Receptor [1]
(Cell-free)
3.9 nM(Ki)
D4 receptor [1]
(Cell-free)
5.1 nM(Ki)
In vivo
In mice, pramipexole (0.001-1 mg/kg s.c.) reduced exploratory locomotor activity. In rats with unilateral striatal lesions, only weak ipsilateral rotation was produced by pramipexole at the highest dose. However, in rats with unilateral lesions of the medial forebrain bundle, pramipexole potently induced contralateral circling (ED50 0.026 mg/kg s.c). In the N-mcthyl-4-phenyl-l,2,3,6 tetrahydropyridine (MPTP) monkey model, pramipexole also had potent stimulatory effects[2]. Pramipexole is, at least in part, transported across the BBB by an organic cation-sensitive transporter. The pramipexole transport is pH-dependent, but sodium- and membrane potential-independent[3].
References

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map